Details about Rena Conti

Access statistics for papers by Rena Conti.

Last updated 2025-06-09. Update your information in the RePEc Author Service.

Short-id: pco1176

Working Papers

2021

1. Common Agent or Double Agent? Pharmacy Benefit Managers in the Prescription Drug Market
   NBER Working Papers, National Bureau of Economic Research, Inc
2. Estimating the Financial Impact of Gene Therapy in the U.S
   NBER Working Papers, National Bureau of Economic Research, Inc View citations (1)

2020

3. Valuing Rare Pediatric Drugs: An Economics Perspective
   NBER Working Papers, National Bureau of Economic Research, Inc View citations (2)

2019

4. Four Facts Concerning Competition in U.S. Generic Prescription Drug Markets
   NBER Working Papers, National Bureau of Economic Research, Inc View citations (2)
   See also Journal Article Four Facts Concerning Competition in US Generic Prescription Drug Markets, International Journal of the Economics of Business, Taylor & Francis Journals (2020) View citations (2) (2020)
5. The Geography of Prescription Pharmaceuticals Supplied to the U.S.: Levels, Trends and Implications
   NBER Working Papers, National Bureau of Economic Research, Inc View citations (1)
6. The Surprising Hybrid Pedigree of Measures of Diversity and Economic Concentration
   NBER Working Papers, National Bureau of Economic Research, Inc View citations (2)

2017

7. The Generic Drug User Fee Amendments: An Economic Perspective
   NBER Working Papers, National Bureau of Economic Research, Inc View citations (2)
8. The Landscape of US Generic Prescription Drug Markets, 2004-2016
   NBER Working Papers, National Bureau of Economic Research, Inc View citations (11)

2015

9. Pricing in the Market for Anticancer Drugs
   NBER Working Papers, National Bureau of Economic Research, Inc View citations (42)
   See also Journal Article Pricing in the Market for Anticancer Drugs, Journal of Economic Perspectives, American Economic Association (2015) View citations (42) (2015)

2014

10. Specialty drug prices and utilization after loss of U.S. patent exclusivity, 2001-2007
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (6)
    See also Chapter Specialty Drug Prices and Utilization after Loss of U.S. Patent Exclusivity, 2001–2007, NBER Chapters, National Bureau of Economic Research, Inc (2016) View citations (2) (2016)

2011

11. The Effect of FDA Advisories on Branded Pharmaceutical Firms' Valuations and Promotion Efforts
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (1)

2006

12. Early Retirement and Public Disability Insurance Applications: Exploring the Impact of Depression
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (12)

Journal Articles

2025

1. The Economics of Generic Drug Shortages: The Limits of Competition
   Journal of Economic Perspectives, 2025, 39, (2), 79-102

2024

2. Stockpiling at the Onset of the COVID-19 Pandemic: An Empirical Analysis of National Prescription Drug Sales and Prices
   Management Science, 2024, 70, (10), 6483-6501

2020

3. Four Facts Concerning Competition in US Generic Prescription Drug Markets
   International Journal of the Economics of Business, 2020, 27, (1), 27-48 View citations (2)
   See also Working Paper Four Facts Concerning Competition in U.S. Generic Prescription Drug Markets, NBER Working Papers (2019) View citations (2) (2019)
4. Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US
   PharmacoEconomics, 2020, 38, (10), 1115-1121
5. Reply to Comment on “Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US”
   PharmacoEconomics, 2020, 38, (12), 1375-1376

2016

6. RESPONSE TO JOYCE AND SOOD
   Journal of Policy Analysis and Management, 2016, 35, (4), 972-974
7. THE ADVANTAGES OF AWARDING THE FEDERAL GOVERNMENT NEGOTIATING POWER OVER THE PRICES OF PRESCRIPTION DRUGS
   Journal of Policy Analysis and Management, 2016, 35, (4), 964-970

2015

8. Pricing in the Market for Anticancer Drugs
   Journal of Economic Perspectives, 2015, 29, (1), 139-62 View citations (42)
   See also Working Paper Pricing in the Market for Anticancer Drugs, NBER Working Papers (2015) View citations (42) (2015)

2010

9. Personalized Medicine and Genomics: Challenges and Opportunities in Assessing Effectiveness, Cost-Effectiveness, and Future Research Priorities
   Medical Decision Making, 2010, 30, (3), 328-340 View citations (4)

Chapters

2016

1. Specialty Drug Prices and Utilization after Loss of U.S. Patent Exclusivity, 2001–2007
   A chapter in Measuring and Modeling Health Care Costs, 2016, pp 273-321 View citations (2)
   See also Working Paper Specialty drug prices and utilization after loss of U.S. patent exclusivity, 2001-2007, National Bureau of Economic Research, Inc (2014) View citations (6) (2014)

2012

2. How do Initial Signals of Quality Influence the Diffusion of New Medical Products? The Case of New Cancer Drug Treatments
   A chapter in The Economics of Medical Technology, 2012, pp 123-148

2009

3. Early Retirement and DI/SSI Applications: Exploring the Impact of Depression
   A chapter in Health at Older Ages: The Causes and Consequences of Declining Disability among the Elderly, 2009, pp 381-408